Multi-indication Pembrolizumab Cost-effectiveness
Abstract
This study aimed to perform a cost-effectiveness analysis evaluating 31 combinations of pembrolizumab use across five solid tumor indications—non-small cell lung cancer (NSCLC), Esophagus, Breast, Melanoma, and Cervical cancer—from the perspective of the Brazilian public health system. The model is uploaded with all data for analysis
Fields of Study & Subjects
Health Systems
Economic Evaluations
Quality of Life
Economic and Financial Impacts of Cancer
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- Mendeley Data
- Publication date
- 10 February 2026
- Language
- EN
- Document type
- Dataset